April 11, 2026 a 01:00 pm
JNJ: Fundamental Ratio Analysis - Johnson & Johnson
Johnson & Johnson (JNJ) remains a stalwart in the healthcare sector, focusing on innovative medicines and medical devices after strategically separating its Consumer Health division. With a stable overall score, it continues to be a reliable long-term investment, although it faces typical industry risks such as regulatory changes and market competition.
Fundamental Rating
The company's overall performance is reflected in its fundamental scores, showcasing a solid financial position with room for improvement in some areas such as debt management.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 3 | |
| Price to Book | 1 |
Historical Rating
Historical ratings provide insight into the consistency of Johnson & Johnson's fundamental strengths and areas of potential improvement over time.
| Date | Overall Score | DCF | ROE | ROA | Debt to Equity | PE | PB |
|---|---|---|---|---|---|---|---|
| 04/10/2026 | 3 | 4 | 5 | 5 | 1 | 3 | 1 |
| N/A | 0 | 4 | 5 | 5 | 1 | 3 | 1 |
Analyst Price Targets
Analysts provide price targets which project a potential upside based on market conditions, with a consensus leaning towards a Buy recommendation.
| High | Low | Median | Consensus |
|---|---|---|---|
| 267 | 190 | 220 | 229.67 |
Analyst Sentiment
The sentiment among analysts reflects a generally positive outlook with a majority recommending Buy, though a few suggest a more cautious approach.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 20 | |
| Hold | 17 | |
| Sell | 3 | |
| Strong Sell | 0 |
Conclusion
Johnson & Johnson exhibits steady growth with a strong presence in innovative healthcare solutions. While facing challenges from debt management and market competition, its robust ROE and asset efficiency reinforce its long-term viability. Analysts remain optimistic, with consensus leaning towards a Buy recommendation, making JNJ an attractive option for growth-oriented investors seeking exposure in the healthcare sector. Nevertheless, potential investors should consider the inherent risks in global healthcare markets.